Exelixis Inc Increase (Decrease) in Accounts Receivable
Exelixis Inc (EXEL) reported Increase (Decrease) in Accounts Receivable of $35.30 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- Exelixis Inc increase (decrease) in accounts receivable for the quarter ending 2026-07-03 was -$6.73M, a 162.83% decline year-over-year.
- Exelixis Inc increase (decrease) in accounts receivable for the quarter ending 2026-04-03 was $42.03M, a 160.75% increase year-over-year.
- Exelixis Inc increase (decrease) in accounts receivable for the quarter ending 2026-01-02 was -$22.81M.
- Exelixis Inc increase (decrease) in accounts receivable for the quarter ending 2025-10-03 was $17.37M.
- Exelixis Inc increase (decrease) in accounts receivable for fiscal 2026 was $21.40M, a 23.44% decline from fiscal 2025.
- Exelixis Inc increase (decrease) in accounts receivable for fiscal 2025 was $27.95M, a 23.55% increase from fiscal 2023.
- Exelixis Inc increase (decrease) in accounts receivable for fiscal 2023 was $22.62M.
- Exelixis Inc increase (decrease) in accounts receivable for fiscal 2022 was -$66.85M, a 154.65% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-07-03 | -$6.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $35.30M 10-Q · filed 2026-08-05 | $12.49M derived: sum of 3 quarters · filed 2026-08-05 | $29.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $42.03M 10-Q · filed 2026-05-05 | $19.22M derived: sum of 2 quarters · filed 2026-05-05 | $36.59M derived: sum of 3 quarters · filed 2026-05-05 | $47.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | -$22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$5.44M derived: sum of 2 quarters · filed 2026-02-10 | $5.28M derived: sum of 3 quarters · filed 2026-08-05 | $21.40M 10-K · filed 2026-02-10 |
| 2025-10-03 | $17.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $28.09M derived: sum of 2 quarters · filed 2026-08-05 | $44.21M 10-Q · filed 2025-11-04 | $39.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $10.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $26.84M 10-Q · filed 2026-08-05 | $22.59M derived: sum of 3 quarters · filed 2026-08-05 | -$104.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $16.12M 10-Q · filed 2026-05-05 | $11.88M derived: sum of 2 quarters · filed 2026-05-05 | -$115.15M derived: sum of 3 quarters · filed 2026-05-05 | $40.90M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | -$4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$131.27M derived: sum of 2 quarters · filed 2026-02-10 | $24.78M derived: sum of 3 quarters · filed 2026-02-10 | $27.95M 10-K · filed 2026-02-10 |
| 2024-09-27 | -$127.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $29.02M derived: sum of 2 quarters · filed 2025-11-04 | $32.19M 10-Q · filed 2025-11-04 | $21.01M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $156.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $159.22M 10-Q · filed 2025-07-28 | $148.04M derived: sum of 3 quarters · filed 2026-02-10 | $163.52M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $3.17M 10-Q · filed 2025-05-13 | -$8.01M derived: sum of 2 quarters · filed 2026-02-10 | $7.48M derived: sum of 3 quarters · filed 2026-02-10 | $6.62M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | -$11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $4.31M derived: sum of 2 quarters · filed 2026-02-10 | $3.44M derived: sum of 3 quarters · filed 2026-02-10 | $22.62M 10-K · filed 2026-02-10 |
| 2023-09-29 | $15.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $14.63M derived: sum of 2 quarters · filed 2024-10-29 | $33.80M 10-Q · filed 2024-10-29 | $33.84M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | -$861.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $18.32M 10-Q · filed 2024-08-06 | $18.36M derived: sum of 3 quarters · filed 2025-02-11 | -$1.84M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $19.18M 10-Q · filed 2024-04-30 | $19.22M derived: sum of 2 quarters · filed 2025-02-11 | -$978.00K derived: sum of 3 quarters · filed 2025-02-11 | $44.12M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$20.16M derived: sum of 2 quarters · filed 2025-02-11 | $24.94M derived: sum of 3 quarters · filed 2025-02-11 | -$66.85M 10-K · filed 2025-02-11 |
| 2022-09-30 | -$20.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $24.90M derived: sum of 2 quarters · filed 2023-11-01 | -$66.89M 10-Q · filed 2023-11-01 | $35.31M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $45.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$46.69M 10-Q · filed 2023-08-01 | $55.51M derived: sum of 3 quarters · filed 2024-02-06 | $63.32M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | -$91.79M 10-Q · filed 2023-05-09 | $10.41M derived: sum of 2 quarters · filed 2024-02-06 | $18.22M derived: sum of 3 quarters · filed 2024-02-06 | $12.84M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $102.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $110.01M derived: sum of 2 quarters · filed 2024-02-06 | $104.63M derived: sum of 3 quarters · filed 2024-02-06 | $122.32M 10-K · filed 2024-02-06 |
| 2021-10-01 | $7.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $2.43M derived: sum of 2 quarters · filed 2022-11-01 | $20.12M 10-Q · filed 2022-11-01 | $15.52M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | -$5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $12.31M 10-Q · filed 2022-08-09 | $7.71M derived: sum of 3 quarters · filed 2023-02-07 | $52.77M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $17.69M 10-Q · filed 2022-05-10 | $13.09M derived: sum of 2 quarters · filed 2023-02-07 | $58.15M derived: sum of 3 quarters · filed 2023-02-07 | $41.89M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | -$4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $40.46M derived: sum of 2 quarters · filed 2023-02-07 | $24.20M derived: sum of 3 quarters · filed 2023-02-07 | $42.47M 10-K · filed 2023-02-07 |
| 2020-10-02 | $45.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $28.80M derived: sum of 2 quarters · filed 2021-11-02 | $47.07M 10-Q · filed 2021-11-02 | -$3.66M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | -$16.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.01M 10-Q · filed 2021-08-05 | -$48.72M derived: sum of 3 quarters · filed 2022-02-18 | $23.53M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $18.27M 10-Q · filed 2021-05-06 | -$32.46M derived: sum of 2 quarters · filed 2022-02-18 | $39.78M derived: sum of 3 quarters · filed 2022-02-18 | $29.66M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | -$50.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $21.51M derived: sum of 2 quarters · filed 2022-02-18 | $11.38M derived: sum of 3 quarters · filed 2022-02-18 | -$43.72M 10-K · filed 2022-02-18 |
| 2019-09-27 | $72.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $62.12M derived: sum of 2 quarters · filed 2020-11-05 | $7.02M 10-Q · filed 2020-11-05 | $79.78M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-28 | -$10.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$65.23M 10-Q · filed 2020-08-06 | $7.53M derived: sum of 3 quarters · filed 2020-08-06 | -$56.46M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-29 | -$55.10M 10-Q · filed 2020-05-05 | $17.66M derived: sum of 2 quarters · filed 2020-05-05 | -$46.33M derived: sum of 3 quarters · filed 2020-05-05 | $19.55M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-28 | $72.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $8.77M derived: sum of 2 quarters · filed 2020-02-25 | $74.65M derived: sum of 3 quarters · filed 2020-02-25 | $85.47M 10-K · filed 2021-02-11 |
| 2018-09-28 | -$63.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $1.89M derived: sum of 2 quarters · filed 2019-10-30 | $12.71M 10-Q · filed 2019-10-30 | |
| 2018-06-29 | $65.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $76.70M 10-Q · filed 2019-07-31 | ||
| 2018-03-30 | $10.82M 10-Q · filed 2019-05-01 | |||
| 2017-12-29 | $43.30M 10-K · filed 2020-02-25 | |||
| 2016-12-30 | $38.68M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |